Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 4/20 | 0.42 |
| ▸ | MMP2 | P08253 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18299060 | 0.87 | KDM4E (0.46) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL3620452 | 0.86 | KDM4E (0.45) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL29813095 | 0.86 | KDM4E (0.45) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL28455744 | 0.86 | ALOX15 (0.55) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL3622667 | 0.86 | KDM4E (0.45) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL23148079 | 0.85 | NOTUM (0.46) | CACNA1H | |
| SCHEMBL8198301 | 0.85 | KDM4E (0.47) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL8200409 | 0.85 | ALDH1A1 (0.53) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL10003164 | 0.83 | KDM4E (0.47) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL700154 | 0.82 | KDM4E (0.51) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370561-B1 | TETRAHYDRO-PYRAZINO[1,2-A]INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | HOFFMANN LA ROCHE (CH) | 2009-02-11 | — | — | EP | disclosed |
| US-6844345-B2 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-01-18 | — | — | US | disclosed |
| US-20020169163-A1 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169163-A1 | Piperazine derivatives | GPR119, SLC5A2, DPP4 | KDM4E 2045/4885ALDH1A1 1203/4885HPGD 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.